



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Poster

ID	N. pgm	Title	Presenting Author
<b>Antiretroviral therapy</b>			
<b>Issues on antiretroviral therapy</b>			
41	P 1	Real-world data on the effectiveness and safety of bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV: 12-month results of the Italian BICSTaR cohort	Andrea Antinori, Roma
94	P 2	Antiretroviral therapy in naïve patients: Perugia's cohort during COVID pandemic	Alessandra Lanzi, Perugia
117	P 3	Durability of doravirine co-formulated with lamivudine and tenofovir disoproxil fumarate in people living with HIV (PLWH)	Francesca Alberton, Milano
155	P 4	Evaluation of switch therapy to antiretroviral regimens with doravirine in people living with HIV	Caterina Candela, Milano
160	P 5	Switching to BICTegravir in ELderly people living with HIV-1 under virologic control: week 96 results from the BICTEL cohort	Alessandro Lazzaro, Roma
171	P 6	Real life experience with Doravirine: impact on metabolic aspects and immune-viral control	Chiara Papalini, Perugia
233	P 7	Strength of 2DR-HIV-therapy in heavy poly-pharmacological treatment of multi-comorbidity patients	Layla Pagnucco, Pavia
264	P 8	Use of doravirine in experienced people living with HIV: a real-life experience	Alessandra Bitti, Sassari
292	P 9	Statin induced anti-HMGCR myopathy in a patient undergoing ARV therapy: a case report	Anastasia Destro, Roma
300	P 10	Cardiovascular risk in PLWHs with IP-based ARV	Nicola Leoni, Cagliari
<b>Issues on new anti-HIV drugs</b>			
76	P 11	Real-life outcomes of Doravirine-based dual regimens as salvage and simplification therapy for multidrug-resistant HIV in a series of seven cases in Lecco Hospital	Valentina Morena, Milano
<b>Clinical HIV</b>			
<b>Late presenters for HIV/AIDS infection</b>			
52	P 12	Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma in the era of HAART: a case report	Marcello Trizzino, Palermo
53	P 13	A fatal case of diffuse large B-cell lymphoma with intestinal perforation in AIDS patient: a case report	Marcello Trizzino, Palermo
60	P 14	Clinical management of an elderly patient, late presenter, with Kaposi's sarcoma and mycobacteriosis	Grazia Pantò, Catania
<b>Management of HIV infections</b>			
51	P 15	Resolved Hepatitis B Virus (HBV) infection and lower nadir of CD4+ are risk factors for progressive increase of CD8+ T-cells absolute count in course of antiretroviral therapy (ART)	Tiziana Mulas, Roma
217	P 16	Does CD4+ T-Lymphocytes count over 200 cell/mm <sup>3</sup> affect the epidemiology of AIDS defining illnesses? An overview from a large Italian clinical center	Valentina Iannone, Roma
<b>Opportunistic infections (OIs)</b>			
298	P 17	Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis associated to Immune Reconstitution Inflammatory Syndrome in a HIV-infected patient	Arianna Forniti, Firenze
<b>Coinfections and Hepatitis</b>			
<b>Bacterial and fungal infections in immunocompromised host</b>			
81	P 18	Hansen's disease, a neglected disease? Case report of a patient with HIV and Mycobacterium Leprae infection	Loredana Alessio, Napoli



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022

Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Poster

ID	N. pgm	Title	Presenting Author
296	P 19	Tropheryma whipplei infection in HIV: report of two cases and literature review	Francesca Raumer, Padova
<b>HCV elimination</b>			
42	P 20	Hepatitis C infection among people who use drugs: a retrospective cohort study using administrative health records	Giaele Moretti, Pisa
212	P 21	HCV prevalence in a over 65 years old population attending general practitioner	Alessandra Di Fraia, Napoli
<b>HDV cure</b>			
163	P 22	Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study	Pietro Lampertico, Milano
<b>Hepatitis epidemiology</b>			
316	P 23	Seroprevalence of HCV-Ab and Awareness in People Who Inject Drugs (PWID) from Addiction Services	Claudia Marcia, Sassari
<b>HIV-associated tuberculosis</b>			
56	P 24	Socio-demographic and clinical characteristics of HIV-associated tuberculosis in Tor Vergata Hospital, Rome: a 9-year analysis	Benedetta Rossi, Roma
<b>Management and treatment of viral hepatitis</b>			
33	P 25	Improving organizational effectiveness for chronic hepatitis C linkage to care and treatment: a case report	Luca Ceccarelli, Pisa
227	P 26	Analysis of patients characteristics and treatment profile of persons who use drugs (PWUD) with and without a co-diagnosis of viral hepatitis C: a real-world retrospective italian study	Francesca Frigerio, Milano
<b>Comorbidities</b>			
<b>Cancers in HIV</b>			
112	P 27	Rare bone involvement of Kaposi's sarcoma in HIV late presenter: a case report	Verena Crosato, Brescia
189	P 28	Outcomes in HIV carriers with or without recurrence of hepatocellular carcinoma after invasive therapy	Costanza Bertoni, Milano
214	P 29	AIDS-defining cancers and non AIDS-defining cancers in a cohort of PLWH	Francesco Ginevri, Ancona
268	P 30	Don't forget prevention, screening with cytology, genotyping and high resolution anoscopy for anal HPV-related precancerous lesions in PLWH continues during COVID19 pandemic	Margherita Digaetano, Modena
<b>HIV and nervous system</b>			
130	P 31	A rare case of HIV-related vacuolar myelopathy in a living patient	Alessandro Giacinta, Udine
<b>Non infectious comorbidities in HIV</b>			
85	P 32	Positive correlation between bone and endothelial damage in patients with HIV	Addolorata Masiello, Caserta
113	P 33	Limb-girdle muscular dystrophy in a patient with recent diagnosis of HIV infection	Davide Checchi, Roma
<b>Sexually Transmitted Infections (STIs)</b>			
98	P 34	Sense and hypersensitivity - A case series of Jarisch-Herxheimer Reaction following gonorrhea treatment	Davide Moschese, Milano
131	P 35	On the importance of the sexual health screening: the impact of a newborn service in the post Covid-19 era in Southern Italy	Eugenio Milano, Bari
157	P 36	Malignant syphilis and a newly HIV infection diagnosis	Giulia Quartini, Terni
<b>COVID-19</b>			
<b>COVID-19 therapies</b>			
48	P 37	Monlupiravir for the early treatment of COVID-19	Debora Altobelli, Perugia



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Poster

ID	N. pgm	Title	Presenting Author
91	P 38	Baricitinib alone and in combination with Remdesivir for the late treatment of adults hospitalized with COVID-19	Mariangela Niglio, Foggia
187	P 39	Type of patients treated with mAb in COVID-19: the reality of Amedeo di Savoia	Carlotta Marchiaro, Torino
254	P 40	Efficacy of Sotrovimab as early COVID treatment of BA.1 sublineage of Omicron variant	Emanuele Drappero, Torino
270	P 41	Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants	Tonino Alonzi, Roma
287	P 42	A possible treatment algorithm for the use of antiviral therapies and monoclonal antibodies against COVID-19	Lucia Diella, Bari
303	P 43	Therapies consumption to treat COVID-19 patients hospitalized in a large tertiary Hospital in Northern Italy during the first three pandemic waves	Emanuele Focà, Brescia
309	P 44	Remdesivir in combination with casirivimab/imdevimab monoclonal antibodies for the treatment of severe COVID-19	Antonio Riccardo Buonomo, Napoli
334	P 45	Monoclonal antibodies administration against SARS-CoV-2. The experience of the Tor Vergata Hospital	Rosario Alessandro Cavasio, Roma
335	P 46	Oral antivirals against SARS-CoV-2: the experience of the Tor Vergata Hospital	Neva Braccialarghe, Roma
339	P 47	SARS COV 2 viral variants and mabs: the results of a cohort study in southern Italy	Loredana Alessio, Napoli
<b>HIV and COVID-19</b>			
170	P 48	Lack of anti-N IgG after symptomatic COVID-19 in an immunocompetent PLWH: a case report	Ylenia Russotto, Messina
175	P 49	COVID-19 Outcomes among people living with HIV in comparison to the General Population of the Lombardy Region	Laura Galli, Milano
178	P 50	Who's no-vax? SARS-CoV2 vaccination adherence in PLWHA: a single center experience. Check to help	Giancarlo Orofino, Torino
265	P 51	The "Unknown"- Lost to follow-up and virological failure in the COVID-19 era: comparison between the three waves, determinants of VF and failure for all causes in PLWH in cART	Laura Montemurro, Foggia
<b>Management of COVID-19</b>			
70	P 52	Acute mesenteric ischemia in a patient with COVID-19 infection: a case report	Gisella D'Aguzzo, Marsala TP
96	P 53	Obesity and Covid-19: the results of a multicentric cohort study in Campania	Verdiana Zollo, Napoli
97	P 54	Epidemiological and clinical factors related to late negativization of SARS-CoV 2 nasopharyngeal swab	Pierantonio Grimaldi, Napoli
99	P 55	Major bleeding events in COVID-19 patients admitted to hospital: a case series	Giacomo Pozza, Milano
101	P 56	Secondary organizing pneumonia (SOP) in two late Covid-19 haematological patients	Andrea Tommasi, Perugia
108	P 57	Campylobacter coli bacteremia in patient with Common Variable Immunodeficiency (CVID) and SARS-CoV-2 infection	Nunzia Esposito, Napoli
256	P 58	Haematological malignancies and COVID-19: do we have effective treatments? A case report	Anita Pupo, Roma
299	P 59	Pre-existing chronic kidney disease (CKD) is associated with an increase in the duration of hospitalization in Covid-19 patients but not with increased mortality: results of a case-control study	Maria Grazia Palamone, Napoli
301	P 60	Evolution of mortality among the first three waves in the largest Italian Hospital receiving SARS-CoV-2 infected patients. Results from the Brescia HUB project	Emanuele Focà, Brescia
308	P 61	A case report of adenovirus infection and HSV-1 hepatitis in a non-transplanted hematological patient with COVID-19 pneumonia	Nicolò Corti, Monza



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Poster

ID	N. pgm	Title	Presenting Author
329	P 62	Overlooked clinical signs in early SARS-CoV-2 infection among elderly people: acute kidney injury and altered state of consciousness	Chiara Fanelli, Sassari
333	P 63	Comparative analysis between the different epidemic waves of SARS - CoV-2 infection: the experience of the Pontine hospital	Paola Zuccalà, Latina
341	P 64	Invasive cryptococcal disease in COVID-19: a case report, Systematic Review of the literature and analysis	Giacomo Ciusa, Palermo
<b>Post-acute COVID-19 syndrome (PASC)</b>			
102	P 65	The use of lung ultrasound to monitoring the lung damage after Covid19 pneumonia	Sara Mazzanti, Ancona
<b>SARS-CoV-2 vaccines</b>			
37	P 66	Safety and immunogenicity of a third-dose COVID-19 BNT162b2 boosting vaccination in People Living with HIV	Laura Gianserra, Roma
44	P 67	Fatal outcome of COVID-19 relapse in a fully vaccinated patient with Non-Hodgkin's lymphoma in maintenance therapy with anti-B cells monoclonal antibodies: a case report	Federica Calò, Napoli
68	P 68	A recent SARS-CoV-2 Omicron variant re-infection shortly after SARS-CoV-2 Delta variant related severe pneumonia in an immunocompromised patient with three-dose vaccination (BNT162b2 mRNA vaccine): immunological characterization and therapeutic approach	Andrea Di Lorenzo, Roma
207	P 69	Evaluation of humoral and T-specific responses after the booster dose of BNT162b2 COVID-19 vaccine in residents of a Long Term Care Facility	Alessia Lai, Milano
250	P 70	Detection of maternal antibodies elicited by COVID-19 vaccination in amniotic fluid	Giuseppina Liuzzi, Roma
318	P 71	Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail patients	Roberta Campagna, Roma
340	P 72	Early evidence on vaccine effectiveness of COVID Vaccines in PLWHA	Monica Sane Schepisi, Roma
<b>Pathogenesis and Immunology</b>			
<b>COVID-19 pathogenesis</b>			
73	P 73	Longitudinal evaluation of QuantiFERON-TB gold plus responses in COVID-19 patients	Grazia Alessio, Roma
86	P 74	Humoral and cellular responses to spike of $\delta$ SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases	Alessandra Aiello, Roma
203	P 75	Serum levels of Surfactant Proteins A and D in SARSCoV2 infected patients	Luca Maddaloni, Roma
266	P 76	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave	Alessandra Aiello, Roma
<b>Social science, Epidemiology and Prevention</b>			
<b>HIV epidemiology and retention in care</b>			
43	P 77	Creation of a model of data collection and survey on long-acting HIV medications in the transgender population	Michele Formisano, Taranto
244	P 78	Anti-HIV antibodies and Avidity Index: comparison between two fourth-generation immunoassays	Alice Morellini, Bologna
<b>HIV prevention (PrEP and PEP)</b>			
31	P 79	The ANLAIDS forum between old and new tools for HIV prevention	Alberto Venturelli, Piacenza
135	P 80	Anlaids in the Schools - What usefulness for adolescents and what impact on their behaviors	Rosario Galipò, Roma



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022

Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Poster

ID	N. pgm	Title	Presenting Author
310	P 81	Role of general practitioners in HIV early diagnosis and prevention: an online local survey	Meriem Jamhour, Latina
330	P 82	Trend of sexually transmitted infections in patients on HIV pre-exposure prophylaxis (PrEP): the experience of two Italian centre between 2019 and 2022	Marianna Menozzi, Modena
<b>Impact of COVID-19 on HIV care</b>			
72	P 83	Home Care Assistance: has Covid-19 had an impact on the complex management of HIV patients?	Alex Dusina, Roma
126	P 84	Impact of COVID-19 on HIV testing: our Lab experience	Elena Garlatti Costa, Pordenone
159	P 85	Has COVID-19 pandemic changed the epidemiology of AIDS-defining illnesses? Data from a large Italian clinical center	Valentina Iannone, Roma
219	P 86	COVID-19 pandemic's impact on the clinical-care management of naïve HIV + patients	Cristina Bitello, Bologna
237	P 87	Impact of COVID-19 pandemic on a HIV Counselling and Testing Site at "D. Cotugno" Hospital, Naples: what lessons can be learned?	Francesco Maria Fusco, Napoli
<b>SARS-CoV-2 epidemiology</b>			
13	P 88	SARS-CoV-2 infection in dialysis patients in Marsala Hospital, Southern Italy: a single-centre experience in a pre- and post-vaccination era, preliminary data	Paola Di Carlo, Palermo
190	P 89	Distribution of SARS-CoV-2 viral variants in a cohort of subjects treated with monoclonal antibodies targeting spike protein in Campania	Alessandra Di Fraia, Napoli
<b>Social and behavioural science, marginalized groups, community aspects and community surveys</b>			
3	P 90	Perceptions of an online serious game activity as formative assessment in higher education applied to a lecture on HIV and sexual health	Stefano Licchelli, Guildford UK
7	P 91	Determinants of Quality of Life in PLWH effectively treated with ART	Franco Maggiolo, Bergamo
9	P 92	A Theatre-Counseling workshop on chemsex: the experience of Plus Roma	Filippo Leserri, Roma
15	P 93	PAMP: Prevention among migrant people: a pilot project	Giulia Valeria Calvino, Roma
17	P 94	Mapping Italian HIV checkpoints and testing centers: the Check Point Index	Monica Carlevari, Pavia
18	P 95	People with HIV - The psychological and social intervention of Anlaids Lazio	Rosario Galipò, Roma
20	P 96	A protocol for a systematic review of predictors of quality of life and health-related quality of life in OPLWHIV	Stefano Licchelli, Guildford UK
30	P 97	HIV and STI awareness project among adolescent population	Federica Rossi, Milano
39	P 98	Nathan Never character by Bonelli Editore combats AIDS and STIGMA	Giacomo Dessì, Cagliari
67	P 99	Villa Maraini: syndemic approach against social stigma	Tania Di Giovanni, Roma
105	P 100	The rise and fall of the news media interest for HIV/AIDS impact on people's life: an observational study of the Italian press	Claudia Capelli, Bologna
136	P 101	Covid 19: let's go with the vaccine Accompanying the booking of the anticovid-19 vaccine for migrants and LGBTI migrants + APS Arcigay Cassero	Roberto Cerbo, Bologna
137	P 102	Measuring impact of a scalable peer education-based sexuality education programme in multiple Arcigay local committees	Nicolò Piazza, Palermo
139	P 103	In and Out testing/counseling approach in pandemic era: a nine months experience at Checkpoint and Hospital center	Giulia Mancarella, Latina
179	P 104	HIV Written Informed Consent: Time to Reconsider the Italian Standard?	Jacopo Testa, Busto Arsizio
216	P 105	Chemsex in Milan	Marco Cusini, Milano
271	P 106	Bringing comprehensive sexuality education into italian lower secondary schools' practice: a pilot study	Eleonora Torri, Pisa



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it 

## Elenco Poster

ID	N. pgm	Title	Presenting Author
294	P 107	Sexual Health in Migrant Population: Analysis of the risk of contracting HIV and STDs	Valentina Manca , Sassari
<b>Virology and Pharmacology</b>			
<b>HIV virology</b>			
10	P 108	Evaluating the dual-target Aptima HIV-1 Quant Dx assay: comparison between viral loads measured with the pol and LTR targets in the same samples	Alessandra Amendola, Roma
240	P 109	Inhibitory activity of the polyphenolic extract of Cistus Monspeliensis L. against HIV -1 under cell culture conditions	Martina Tamburello, Bologna
247	P 110	Evaluation of a new real-time PCR commercial test for HIV-DNA quantification in PBMC	Tiziano Giacomo Alice, Torino
<b>Pharmacology, pharmacogenomics and drug interactions</b>			
64	P 111	Exploratory analysis of potential drug-drug interactions between molnupiravir and HAART in PLWH with COVID-19 in Udine	Denise D'Elia, Udine
225	P 112	Dolutegravir plasma and intracellular pharmacokinetics in the clinical setting	Francesca Alladio, Torino
226	P 113	Isoenzymes subfamilies and symptomatic adverse events: is there a link?	Elio Gentilini Cacciola, Roma
<b>SARS-CoV-2 virology</b>			
109	P 114	Discerning the molecular mechanism beyond the UV-photoinactivation of SARS-CoV-2	Sergio Strizzi, Milano
243	P 115	Qualitative and quantitative approach to SARS-CoV-2 RNA detection	Chiara Orlandi, Urbino
<b>Vaccines (other than SARS-CoV-2)</b>			
193	P 116	Persistence of immune responses after the administration of the meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) in HIV-vertically transmitted young patients	Claudia Vanetti, Milano